Stromelysin-1 promoter 5A/6A polymorphism is an independent genetic prognostic risk factor and interacts with smoking cessation after index premature myocardial infarction

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 9, 2005, Pages 1998-2005

  Liu, P Y ^a,b   Li, Y H ^a   Tsai, W C ^a   Tsai, L M ^a   Chao, T H ^a   Wu, H L ^c   Chen, Jyh Hong ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Acute myocardial infarction; Matrix metallo proteinase; Polymorphism; Prognosis; Smoking cessation; Stromelysin 1

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STROMELYSIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC PREDISPOSITION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION; UNIVARIATE ANALYSIS;

ADULT; AGE OF ONSET; ALLELES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS (GENETICS); RISK FACTORS; SMOKING CESSATION;

EID: 30644469732     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01515.x     Document Type: Article

References (39)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndrome. Circulation 2001; 104: 365-72.
3. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atheroslcerotic plaques. Circulation 1995; 92: 1565-9.
4. Woessner JJ. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-54.
5. Liu PY, Tsai WC, Lin CC, Hsu CH, Chen JH. Invasive measurements of pulse wave velocity correlate with the degree of echocardiographic aortic valve calcification and severity associated with matrix metalloproteinases among elders with aortic valve stenosis. Clin Sci (London) 2004; 107: 415-22.
6. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73: 209-15.
7. Beyzade S, Zhang S, Wong YK, Day IN, Eriksson P, Ye S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol 2003; 41: 2130-7.
8. Terashima M, Akita H, Kanazawa K, Inoue N, Yamada S, Ito K, Matsuda Y, Takai E, Iwai C, Kurogane H, Yoshida Y, Yokoyama M. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99: 2717-19.
9. Liu PY, Chen JH, Li YH, Wu HL, Shi GY. Synergistic effect of stromelysin-1 (matrix metalloproteinases-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost 2003; 90: 132-9.
10. Humphries S, Bauters C, Meirhaeghe A, Luong L, Bertrand M, Amouyel P. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene as a risk factor for restenosis. Eur Heart J 2002; 23: 721-5.
11. Ghilardi G, Biondi ML, DeMonti M,Turri O, Guagnellini E, Scorza R. Matrix metalloproteinase-1 and matrix melalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke 2002; 33: 2408-12.
12. Anderson JL, King GJ, Bair TL, Elmer SP, Muhlestein JB, Habashi J, Carlquist JF. Association between a polymorphism in the gene encoding glycoprotein Ilia and myocardial infarction and coronary artery disease. J Am Coll Cardiol 1999; 33: 727-33.
13. Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, d'Addedda M, Di Minno G. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997; 77: 605-6.
14. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-I) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTlM study. Thromb Haemost 1995; 74: 837-41.
15. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-6.
16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuve LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
17. Wang LX, Sim AS, Badenhop RF. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Meet 1996; 2: 41-5.
18. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ. Lindpaintner K. P1A1/A2 polymorphism of platelet glycoprotein IIIa and risk of myocardial infarction, stroke and venous thrombosis. Lancet 1997; 349: 385-8.
19. Li YH, Chen JH, Tsai WC, Chao TH, Guo HR, Tsai LM, Wu HL. Shi GY. Synergistic effect of thrombomodulin promoter -33G/A polymorphism and smoking on the onset of acute myocardial infarction. Thromb Haemost 2002; 87: 86-91.
20. Doll R. Hill AB. Mortality of British doctors in relation to smoking: observation on coronary thrombosis. Natl Cancer Inst Monogr 1996; 19: 205-68.
21. Allen DR, Browse NL, Rutt DL, Butler L, Fletcher C. The effects of cigarette smoke, nicotine, and carbon monoxide on the permeability of the arterial wall. J Vasc Surg 1988; 7: 139-52.
22. Blann AD. The acute influence of smoking on the endothelium. Atherosclerosis 1992; 96: 249-50.
23. Tsiara S, Elisaf M, Mikhailidis DP. Influence of smoking on predictors of vascular disease. Angiology 2003; 54: 507-30.
24. Li YH, Chen JH, Guo HR, Tsai WC, Chao TH. Genetic risk factors associated with the prognosis of myocardial infarction in young patients. Thromb Haemost 2002; 88: 694-7.
25. Sacks FM, Pfeffer MA. Move LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR. Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol And Recurrent Event trial investigators. N Engl J Med 1996; 335: 1001-9.
26. Teng JK, Lin LJ, Tsai LM, Kwan CM, Chen JH. Acute myocardial infarction in young and very old Chinese adults: clinical and therapeutic implications. Int J Cardiol 1994; 44: 29-36.
27. Liu PY, Tsai WC. Lin LJ, Li YH, Chao TH, Tsai LM, Chen JH. Time domain heart rate variability as a predictor of long-term prognosis after acute myocardial infarction. J Formas Med Assoc 2003; 102: 474-9.
28. Haustein UF, Anderegg U. Premature skin aging caused by smoking. Hautarzt 2000; 51: 807-8.
29. Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese Jr RJ, Chapman Jr HA, Shapiro SD, Elias JA. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 2000; 106: 1081-93.
30. Sharp DS, Benowitz NL, Bath PM, Martin JF, Beswick AD, Elwood PC. Cigarette smoking sensitizes and desensitizes impedance-measured ADP-induced platelet aggregation in whole blood. Thromb Haemost 1995; 74: 730-5.
31. Carty CS, Soloway PD, Kayastha S, Bauer J, Marsan B, Ricotta JJ. Dryjski M. Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells. J Vasc Surg 1996; 24: 927-34.
32. Barua RS, Ambrose JA, Saha DC, Bales-Reynolds LJ. Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors: an in vitro demonstration. Circulation 2002; 106: 905-8.
33. Rundek T, Elkind MS, Pittman J, Boden-Albala B, Martin S, Humphries SE, Juo SH, Sacco RL. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 2002; 33: 1420-3.
34. Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, Bouchard C, Toyry J, Humphries SE. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2657-62.
35. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
36. Shepherd J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesteremia. N Engl J Med 1995; 333: 1301-7.
37. Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Registry). J Am Coll Cardiol 1995; 26: 654-61.
38. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143-421.
39. Addala S, Grines CL, Dixon SR, Stone GW, Boura JA, Ochoa AB, Pellizzon G, O'Neill WW, Kahn JK. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). Am J Cardiol 2004; 93: 629-32.